Figure 2. VR1 agonists increased the expression of SIINFEKL-H-2Kb complexes in mice infected with VV-OVA. Mice were orally administered CP or RTX for 3 days, infected with VV-OVA, and then treated with the same doses of CP or RTX for consecutive 5 days, as described in Fig. 1. DCs were isolated from the lymph nodes and spleens. (A) The amounts of Kb-OVA peptide complexes on the cell surface were directly determined using the F(ab')2 fragment of a SIINFEKL-H-2Kb-specific mAb (25-D1.16). (B) Expression levels of H-2Kb and I-Ab molecules. Blue dotted line, isotype control; green shaded area, DCs from mice not treated with a VR1 agonist (CP or RTX); red line, DCs from VR1 agonist-treated mouse.
